Biodefense Market Analysis By Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear, Others) By Region (North America, Europe, Asia Pacific, Latin America, Mea) And Segment Forecasts, 2018 To 2025

Market Size and Trends

The global biodefense market size was over USD 9.5 billion in 2015. The market is expected to witness growth owing to technological advancements in pathogen detection techniques in the forensic division. Some of the recent technologies applied in biodefense are database management systems, nanotechnology, gene chips, and advanced detector hardware. The growing production of vaccines, rapid diagnostic procedures, better forensic and detection therapies, and prophylactics is one of the pivotal factors expected to strengthen the biodefense capabilities across the world over the forecast period.

Increasing investment by the regional government in matured economies, such as the U.S. and Europe,for biodefense preparedness is likely to fuel the growth over the forecast period. Based on the report published by the Centre for Research on Innovation and Science Policy, it was stated that the number of grants allocated bythe National Institutes of Health (NIH) for the development of bioweapon agents, such as anthrax, plague, glanders, tularemia, and brucellosis, had increased by 15 times during the years, 1996-2001.As a result of the increase in the number of foreign-owned and co-owned patents, the number of international collaborations, subcontracting, and technological cooperation agreements are growing, which are thus anticipated to propel the demand in the coming few years.

Biodefense Market Revenue, By Product, 2014 - 2025 (USD Million)

Additionally, growing government intervention in terms of advancing various initiatives, such as the BioShield initiative undertaken in 2004, and creating incentives for private biotech firms to develop and manufacture new vaccines against CDC-defined category A bioterrorism threats, such as botulism, tularemia, and viral hemorrhagic fevers like Ebola. The resultant market opportunity has led to collaborations amongst the private players and with various international biotechnology companies in regions, such as France, Japan, Denmark, Austria, Belgium, the Netherlands, and the UK, to develop countermeasures against biological threat agents. The joint endeavors undertaken by the private and public sector in this verticalare expected to boost the demand growth.

Product Insights

Anthrax was the largest application segment and accounted for a share of over 31.3% in 2015.The growing interest and efforts of private players in expanding the product portfolio catering to anthrax prevention is anticipated to impel the market growth in the future.Growing government funding in the U.S. to generate and stock sufficient vaccines against anthrax through various programs, such as BioShield Legislation, Biomedical Advanced Research and Development Authority (BARDA), and Joint Program Executive Office for Chemical and Biological Defense, is creating profitable opportunities for this vertical. One of the U.S. FDA-approved products against anthrax is Biothrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.

The other products segment accounted for around 15% of the global market in 2015 and is expected to grow at a CAGR of over 8.3% from 2016 to 2025.The viral hemorrhagic segment (a part of the others segment) is identified as the most lucrative segment. Rapid rise in R&D investments following the 2014-2015 Ebola outbreaks and growing awareness regarding the possibility of the virus being used as a bioweapon attributes to the aforementioned conclusion. The radiation segment is also expected to witness rapid growth during the forecast period. The market is driven by growth in the research and development initiatives followingthe nuclear crisis in Japan.

Regional Insights

North America emerged as the largest segment accounting for more than half of the global market in 2015.Government initiatives pertaining to funding for biological defense mechanism is a major factor pushing the growth of this market.However, fluctuations in funding due to changing government policies may impede demand during the forecast period. For example, in 2013, the CDC experienced deficits worth USD 13.0 million in its biological defense program budget, while the budget allocated for NIH was reduced by 5%. This budget cut affected the manufacturing process pertaining to ZMapp, a therapeutic drug believed to be effective against Ebola. The presence of variousongoing programs under the organizations such asHHS, BARDA, NIAID, CDC, ASPR, and the FDA,was one of the key contributing factors for the revenue generationin North America in 2015.

U.S. Biodefense market share, by product, 2016

Asia Pacific is expected to witness a significant demand on account of surging investments in the R&D sector. Australia and Japan are two of the most matured Asia Pacific markets. The extensive vaccine manufacturing facilities present across Japan coupled with the presence of sophisticated healthcare infrastructure in the country is contributing to its strong market position. Australia has the Communicable Disease Network Australia (CDNA),one such facility that works toward counteracting disease outbreaks and the deliberate release of dangerous pathogens.

Market Share

Key industry participants include Xoma Corporation;PharmAthene, Inc.;Emergent BioSolutions, Inc.;Dynavax Technologies Corporation;SIGA Technologies;Elusys Therapeutics, Inc.;Ichor Medical Systems;DynPort Vaccine Company, LLC;Cleveland BioLabs;Bavarian Nordic;Achaogen, Inc.;Nanotherapeutics, Inc.; and Alnylam Pharmaceuticals, Inc.Some of the key industry participants such as PharmAthene, Inc.; Emergent Biosolutions, Inc.;Ichor Medical Systems; and few others areactively engaged informing ongoing biodefense contracts to widen their product pipelines.

Report Scope

*15% free customization - It is equivalent to work done by a research analyst for 5 working days

Market Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the market trends in each of the sub-markets from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the biodefense market on the basis of product, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)
  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/Nuclear Defense
  • Others
• Regional Outlook (Revenue, USD Million, 2014 - 2025)
  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • South Africa